XOVOLTIB 40MG TABLET

Xovoltib 40Mg Tablet contains Afatinib Dimaleate, a potent EGFR tyrosine kinase inhibitor (TKI) used in the treatment of EGFR mutation-positive non-small cell lung cancer (NSCLC). This oral targeted therapy works by blocking EGFR signaling pathways, helping to control cancer cell growth and proliferation. Xovoltib is prescribed under strict oncologist supervision to ensure safe and effective treatment outcomes.

Afatinib dimaleate in Xovoltib binds irreversibly to EGFR, inhibiting the pathways responsible for tumor progression. The tablet is effective in slowing the growth of NSCLC and managing symptoms related to the disease. Its oral formulation provides convenient dosing, allowing patients to receive targeted cancer therapy outside hospital settings while maintaining adherence to oncologist guidance.

Manufactured in WHO-GMP certified facilities, Xovoltib 40 mg Tablet ensures high standards of quality, safety, and efficacy. It is a trusted anticancer targeted therapy used for the treatment of non-small cell lung cancer (NSCLC). This chemotherapy medicine is specifically designed for patients with EGFR mutation-positive tumors, supporting improved clinical outcomes when used as part of a comprehensive oncology treatment plan.

Product Features

• Targeted EGFR tyrosine kinase inhibitor
• Contains Afatinib Dimaleate 40 mg
• Used in EGFR-mutated NSCLC
• Oral, once-daily dosing (as prescribed)
• Helps inhibit cancer cell proliferation
• Suitable for first-line or subsequent therapy (as advised)
• Manufactured under GMP standards
• Oncology prescription medicine

How It Helps

• Blocks EGFR signaling pathways to inhibit tumor growth
• Slows the proliferation of cancer cells in NSCLC
• Effective in treating EGFR mutation-positive tumors
• Supports targeted oral therapy under oncologist supervision